The global breast biopsy market was estimated to be $658 million in 2020 and is estimated to reach $1082 million in 2030 with an expected CAGR of 5.1% from 2021 to 2030.Breast biopsy is a significant medical technology that is used in detection of irregular growth of cells and tissues for determination of underlying cancerous behavior possession. The Breast Biopsy market may be segmented using a variety of approaches.Breast biopsies are commonly done with Fine Needle Aspiration Biopsy, which is one of the least invasive procedures available and leaves no scarring. A needle is introduced through the dermal tissue of the breast to remove tissue. The other method involves using ultrasound radiation to guide the biopsy, which is also known as stereotactic needle biopsy in conjunction with a mammogram. During this treatment, the ultrasound monitor guides the needle to the target spot in the breast. Stereotactic mammography uses images acquired from various angles to pinpoint the site of the breast tumor, as well as where the needle will be put to get a breast biopsy sample.
Breast biopsy is a diagnostic process used to see if a small sample of breast tissue removed is malignant or not. A breast biopsy helps in locating the diseased tissue in breast and helps in further diagnosis. Factors that contribute to the rise in breast biopsy market are surge in consumption of alcoholic drinks, lack of exercise, and improper dietary habits. With surge in hormonal imbalance as a result of unhealthy lifestyle is also considered as a prominent factor that contributes in the rise of the market. However, limited awareness among female population and substandard healthcare facilities are factors that restrain the growth of breast biopsy market.
The pandemic of COVID-19 is predicted to have a detrimental impact on breast biopsy market growth. The pandemic had a number of negative consequences for breast biopsy market growth due to shutdown in services related to cancer screening. Owing to lockdowns in several nations to prevent the spread of COVID-19, hospitals, clinics, and diagnostic facilities were unable to deliver biopsy services. The surgeries got delayed due to risk of infections and use of protective equipment and hospital resources was limited to the COVID patients, thus creating a negative impact on breast biopsy market.
The breast biopsy market is segmented on the basis of product, image guided technology, end user, and region. On the basis of product, it is categorized into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). By image guided technology, it is classified into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into clinics diagnostic centers and hospitals. By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Germany, Russia, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, Singapore, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Israel, Saudi Arabia, South Africa, and rest of LAMEA).
The list of key players included in the report include Becton, Dickinson & company, Hologic, Inc., Cell-Signalling Technology, Danaher, QIAGEN, Illumina, Fujifilm, Medtronic, Bio-rad and Thermo Fisher Scientific Corp.
The other players in the value chain include Zenalux Biomedical, Inc., F. Hoffmann-La Roche Ltd., OncoCyte Corporation, Laboratory Corporation of America Holdings (Labcorp), Scion Medical Technologies, Planmed Oy, Aurora Imaging Technology Inc., Carestream Health, Cardinal Health, and PerkinElmer.
Breast biopsy is a diagnostic process used to see if a small sample of breast tissue removed is malignant or not. A breast biopsy helps in locating the diseased tissue in breast and helps in further diagnosis. Factors that contribute to the rise in breast biopsy market are surge in consumption of alcoholic drinks, lack of exercise, and improper dietary habits. With surge in hormonal imbalance as a result of unhealthy lifestyle is also considered as a prominent factor that contributes in the rise of the market. However, limited awareness among female population and substandard healthcare facilities are factors that restrain the growth of breast biopsy market.
The pandemic of COVID-19 is predicted to have a detrimental impact on breast biopsy market growth. The pandemic had a number of negative consequences for breast biopsy market growth due to shutdown in services related to cancer screening. Owing to lockdowns in several nations to prevent the spread of COVID-19, hospitals, clinics, and diagnostic facilities were unable to deliver biopsy services. The surgeries got delayed due to risk of infections and use of protective equipment and hospital resources was limited to the COVID patients, thus creating a negative impact on breast biopsy market.
The breast biopsy market is segmented on the basis of product, image guided technology, end user, and region. On the basis of product, it is categorized into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). By image guided technology, it is classified into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into clinics diagnostic centers and hospitals. By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Germany, Russia, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, Singapore, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Israel, Saudi Arabia, South Africa, and rest of LAMEA).
The list of key players included in the report include Becton, Dickinson & company, Hologic, Inc., Cell-Signalling Technology, Danaher, QIAGEN, Illumina, Fujifilm, Medtronic, Bio-rad and Thermo Fisher Scientific Corp.
The other players in the value chain include Zenalux Biomedical, Inc., F. Hoffmann-La Roche Ltd., OncoCyte Corporation, Laboratory Corporation of America Holdings (Labcorp), Scion Medical Technologies, Planmed Oy, Aurora Imaging Technology Inc., Carestream Health, Cardinal Health, and PerkinElmer.
Key Benefits For Stakeholders
- The study gives a top to bottom investigation of the breast biopsy market, with most recent things and future appraisals to explain the imminent investment pockets.
- It gives a quantitative investigation from 2020 to 2030 to engage the accomplices to gain by prevailing market opportunities.
- Wide investigation by product type and end user determines the various trends and prevailing opportunities in the different market.
- Complete examination of all land regions is given, which assist with determining the main opportunities.
- Key market players are profiled and their strategies are investigated totally to expect the relentless standpoint of the market.
Key Market Segments
By Product
- Vacuum Assisted Biopsy
- Core Needle Biopsy
- Fine Needle Aspiration Biopsy
By Image Guided Technology
- Mri Guided Breast Biopsy
- Ultrasound Guided Breast Biopsy
- Mammography Guided Stereotactic Biopsy
- Ct Guided Biopsy
- Other Image Guided Breast Biopsy
By End User
- Hospitals And Clinics
- Diagnostic Centers
By Region
- Europe
- Germany
- U.K.
- Italy
- France
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- North America
- U.S.
- Canada
- Mexico
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Ethicon Endo Surgery
- Intact Medical Corporation
- Galini SRL
- Hologic Inc.
- Leica Biosystems Nussloch GmbH
- C. R. Bard, Inc.
- Becton and Dickinson Company
- Argon Medical Devices
- Cook Medical Incorporated
- Encapsule medical Devices LLC.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: BREAST BIOPSY MARKET, BY PRODUCT
CHAPTER 5: BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY
CHAPTER 6: BREAST BIOPSY MARKET, BY END USER
CHAPTER 7: BREAST BIOPSY MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Breast Biopsy Market,' the breast biopsy market was valued at $658.17 million in 2020, and is estimated to reach $1.1 Billion by 2030, growing at a CAGR of 5.1% from 2021 to 2030.Breast biopsies are the tests that are used to detect area with an abnormal tissue growth or help in diagnosis of breast cancer. Defects and abnormalities in the cells can be detected with help of vacuum assisted biopsy, core needle, and fine needle biopsy. In addition, assisting the surgeons or radiologist to perform biopsy using specialized imaging equipment, such as ultrasound, mammography-guided stereotactic biopsy helps in advanced and better detection of cancerous or abnormal tissue and cell growth.
Breast biopsy is a medical technique that helps to examine the suspicious growth region of breast. It helps in diagnosis of irregular growth of cells and tissues in order to determine whether they are cancerous. It takes a sample of breast tissue to discover the growth of breast lumps & other abnormalities and helps in further observation of malignant behavior of cells. It is regarded as a reliable approach for cancer detection.
When a person is exposed to symptoms of sore breast, breast lump, breast dimpling, peeling of breast, and nipple discharge, they are recommended to opt for breast biopsy in comparison to invasive surgical procedures as invasive surgical procedures for breast biopsy have been found to be ineffective since they are uncomfortable.
The factors that surge the breast biopsy market growth are rise in concerns of mammary cancer in all countries, as well as awareness campaigns & screenings done in the favor of the hereditary gene BRCA1 and BRCA 2. Moreover, technological advancements and increased adaptive mammography-guided stereotactic biopsy are projected to provide a significant growth in the near future. Although, the market has benefited from the cultivating research environment, which has contributed in the development of more accurate and minimally invasive procedures for the early identification of mammary cancer. Governments have also tried to create a stable and comprehensive environment for cancer research, which has aided the development of these diagnostic technologies.
The pandemic had a number of negative consequences on breast biopsy market growth. Owing to lockdowns in several nations to prevent the spread of COVID-19, hospitals, clinics, and diagnostic facilities were unable to deliver biopsy services. With delay in treatments and priority of COVID diagnosis held the market to face a negative consequence. A relaxation in the pandemic situation enforced the hospitals to be focused on the delayed appointments, which helped the market regain its growth. Overall, COVID-19 initially had a negative impact on breast biopsy market however after relaxation in the situation and surge in regulatory approvals, the market possessed a positive impact.
The breast biopsy market size is segmented on the basis of product, image guided technology, end user, and region. On the basis of product, it is categorized into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). By image guided technology, it is classified into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into clinic diagnostic centers and hospitals. Geographically, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Germany, Russia, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, Singapore, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Israel, Saudi Arabia, South Africa, and rest of LAMEA).
By product, the breast biopsy market size is divided into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and others. Based on type, breast biopsy market analysis include needle breast biopsy (core needle biopsy (CNB), fine-needle aspiration biopsy (FNAB), vacuum-assisted biopsy (VAB)), open surgical breast biopsy (excisional, incisional), liquid breast biopsy (circulating tumor cells, circulating tumor DNA (ctDNA), and other biomarkers.
On the basis of image guided technology, the market is fragmented into image-guided biopsy (mammography-guided stereotactic biopsy, ultrasound-guided biopsy, MRI-guided biopsy, other guidance techniques) and liquid biopsy (NGS-based Biopsy, PCR-based biopsy, microarray-based biopsy). In addition, breast biopsy has application across early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.
Key findings of the Study
- The study gives a top to bottom investigation of the breast biopsy industry, with most recent things and future appraisals to explain the imminent investment pockets.
- The breast biopsy market forecast is studied for a period of 2021 to 2030.
- It gives a quantitative investigation from 2020 to 2030 to engage the accomplices to gain by prevailing market opportunities.
- Wide investigation by product type and end user determines the various trends and prevailing opportunities in the different market.
- Complete examination of all land regions is given, which assist with determining the main opportunities.
- Key market players are profiled and their strategies are investigated totally to expect the relentless standpoint of the market.
Companies Mentioned
- Ethicon Endo Surgery
- Intact Medical Corporation
- Galini SRL
- Hologic Inc.
- Leica Biosystems Nussloch GmbH
- C. R. Bard, Inc.
- Becton and Dickinson Company
- Argon Medical Devices
- Cook Medical Incorporated
- Encapsule medical Devices LLC.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
